- 메뉴 바로가기
- 주메뉴 바로가기
- 컨텐츠 바로가기
- Current ~ 2020
- 2019 ~ 2016
- 2015 ~ 2012
- 2011 ~ 1999
Current ~
2020
2024
- 12
- Incorporation into Huons Group affiliates
- 10
- Registered patent(Antibody to be cross-linked to human and mouse SEMA3A and thereof, Brazil)
- 09
- Registered the biosimilar EPO product(Panpotin) in Thailand
- 07
- Registered patent(Ophthalmic liquid composition) in Korea
- 02
- Received the certificate of GMP compliance of a manufacturer
2023
- 11
- Registered patent(Anti-Blood coagulation factor VIII antibody and uses thereof , India)
- 08
- Registered the biosimilar EPO product(Panpotin 6000IU, 10000IU) in Korea
- 08
- Registered the biosimilar EPO product(Panpotin) in Saudi
- 06
- Registered patent(Anti-Blood coagulation factor VIII antibody and uses thereof , China)
- 02
- Registered patent(Nano-antibody capable of binding to SFTSV and application thereof) in Korea
2022
- 10
- Registered the biosimilar EPO product(ERYSAA 2000IU) in Philippines
- 08
- Registered the biosimilar EPO product(ERYSAA 4000IU) in Philippines
- 07
- Applied patent(Lipid nanoparticles for protein delivery) in Korea
- 02
- Applied patent(Novel fusion proteins derived from coronaviruses and thereof) in Korea
- 02
- Registered patent(Antibody to be cross-linked to human and mouse SEMA3A and thereof, Mexico)
2021
- 09
- Received the approval of rhFactor VIII phase III clinical trial from MFDS
- 09
- Registered patent(Anti-Blood coagulation factor VIII antibody and uses thereof , USA)
- 08
- Registered patent(Antibody to be cross-linked to human and mouse SEMA3A and thereof, China)
- 07
- Registered patent(Expression vector for animal cell, Brazil)
- 06
- Submitted the IND for rhFactor VIII phase III clinical trial in MFDS
- 05
- Registered patent(Antibody to be cross-linked to human and mouse SEMA3A and thereof, JP)
- 03
- Received the certificate of GMP compliance of a manufacturer(PIC/s cGMP)
2020
- 09
- Registered patent(Antibody to be cross-linked to human and mouse SEMA3A and thereof, Indonesia)
- 02
- Received the HALAL certificate of EPO biosimilar
- 02
- Registered patent(Antibody to be cross-linked to human and mouse SEMA3A and thereof, USA)
- 02
- EPO biosimilar marketing license contract with Vietnam Khuong Duy
- 01
- EPO biosimilar marketing license contract with Korea Joonghun pharma
2019 ~
2016
2019
- 11
- Registered the biosimilar EPO product(Panpotin) in Korea
- 11
- Registered patent(Antibody to be cross-linked to human and mouse SEMA3A and thereof, Australia)
- 10
- Registered patent (Expression vector for animal cell, Malaysia)
- 06
- Registered patent(Anti-Blood coagulation factor VIII antibody and uses thereof , Korea)
- 03
- EPO biosimilar marketing license contract with SaudiVax, KSA
- 03
- Received the approval of PGA40(rhFVIII) Phase I clinical trial from MFDS
- 01
- Registered the biosimilar EPO product(ERYSAA) in Malaysia
2018
- 10
- Submitted the IND for recombinant FVIII clinical trial in MFDS
- 05
- Submitted the NDA for biosimilar EPO in MFDS
- 04
- Registered patent (Antibody to be cross-linked to human and mouse SEMA3A,and use thereof, KR)
- 04
- Received the certificate of GMP compliance of a manufacturer(PIC/S cGMP)
- 04
- Received the certificate of a pharmaceutical product(ERYSAA) for export in MFDS (Ingredient: Epoetin alfa )
2017
- 09
- PDA10 phase III clinical trial is completed
- 03
- Submitted the NDA for biosimilar EPO in Malaysia NPRA
2016
- 11
- Registered patent (Expression vector for animal cell, EU)
- 08
- Recombinant FVIII marketing license contract with Mexico Medicamentos Naturales
- 07
- Received the certificate of PIC/S cGMP for biosimilar EPO product from Malaysia NPCB
- 04
- Registered patent (Expression vector for animal cell, JP)
- 03
- listed company in KOSDAQ
2015 ~
2012
2015
- 11
- Biosimilar EPO marketing license contract with Turkey ONKO Co.
- 10
- Registered patent (Expression vector for animal cell, CN)
- 08
- Biosimilar EPO marketing license contract with Thailand S.charoen Co.
- 08
- Nominated K-brain power company from MOTI
- 06
- Registered patent (Expression vector for animal cell, US)
- 05
- Initiated Factor VIII preclinical study
- 02
- Completed biosimilar G-CSF preclinical study
2014
- 07
- “Minister Award for National R&D Excellence” from Ministry of Science, ICT and Future Planning
- 04
- Registered patent (Expression vector for animal cell, KR)
- 01
- Initiated PDA10 phase III clinical trial in Malaysia and korea
2013
- 11
- Received the certificate of PIC/S cGMP from Malaysia NPCB
- 09
- Minister Award for Biotechnology Excellence from MOTIE
(Ministry of Trade, Industry & Energy)
- 07
- Award fund of Gyeonggi-do local government project (Biosimilar G-CSF,475 Million KRW/2 years)
- 07
- Initiated PDA10 phase III clinical trial from KFDA
2012
- 12
- Received the approval of PDA10 Phase III clinical trial from KFDA
- 09
- Completed clinical trial phase I of biosimilar EPO and Submit IND for clinical trial phase III
- 06
- Joint clinical trial phase III and EPO marketing license contract with Malaysia CCMB company
- 06
- Received the approval of PDA10 Phase I clinical trial from KFDA
2011 ~
1999
2011
- 11
- Registered patent (Expression vector for animal cells, IN)
- 05
- Approved as a medicine manufacturer by KFDA
- 03
- Registered patent (Expression vector for animal cells, MY)
- 02
- Received the certificate of factory registration
2010
- 08
- Construction of GMP plant
- 04
- Received the certificate for company’s affiliated research institute
- 03
- Received the certificate of venture business
- 02
- Purchase apartment-type factory (1800 m².)
- 01
- Re-founded PanGen Biotech Inc.
2006
- 03
- Acquired the Bio-business unit and Key professionals in Samsung Fine Chemicals Co.
1999
- 12
- Established PanGen Biotech Inc.
